Related Experiment Videos
Duodenal perforation associated with tolazoline
Archives of Disease in Childhood
|September 1, 1985
Summary
Tolazoline, used for pulmonary hypertension in neonates with congenital diaphragmatic hernias, may cause duodenal perforations. Strategies to mitigate these gastrointestinal side effects are discussed.
Area of Science:
- Neonatal Medicine
- Pediatric Surgery
- Pharmacology
Background:
- Congenital diaphragmatic hernia (CDH) repair requires management of persistent pulmonary hypertension of the newborn (PPHN).
- Tolazoline is a vasodilator used to treat PPHN in neonates.
- Gastrointestinal complications are a known risk in neonates undergoing CDH repair.
Observation:
- A neonate treated with tolazoline for PPHN post-CDH repair developed a duodenal perforation.
- This adverse event highlights a potential gastrointestinal side effect of tolazoline therapy.
Findings:
- The study discusses the potential role of tolazoline in causing duodenal perforation in this specific clinical context.
- Analysis of tolazoline's mechanism of action and its impact on the gastrointestinal system.
Implications:
- Proposes potential measures to reduce the incidence of gastrointestinal side effects associated with tolazoline.
- Informs clinical practice regarding the safe use of tolazoline in neonates with CDH and PPHN.
- Suggests the need for vigilant monitoring for gastrointestinal complications in neonates receiving tolazoline.